Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of $499, down from $650, takes effect immediately.

Novo Nordisk A/S ($NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.